August 5, 2020

The Niche

Knoepfler lab stem cell blog

Teva

2 min read

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner Teva choosing to end their relationship with Mesoblast on a stem cell heart disease trial. Mesoblast spun this as something good that they regained the rights from Teva, but investors …Read More